Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYH Community Health Systems	$3.38 +2.0%	$3.33	$2.24 ▼ $6.29	$464.41M	2.12	2.39 million shs	2.14 million shs
EDIT Editas Medicine	$2.10 -5.4%	$1.69	$0.91 ▼ $6.05	$185.84M	2.1	2.56 million shs	1.78 million shs
FDMT 4D Molecular Therapeutics	$3.77 -8.7%	$3.62	$2.24 ▼ $28.93	$191.32M	2.84	826,195 shs	725,400 shs
MLYS Mineralys Therapeutics	$13.77 +2.2%	$14.84	$8.24 ▼ $18.38	$878.56M	-0.18	531,995 shs	793,529 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYH Community Health Systems	+1.84%	+6.43%	-8.01%	+19.72%	+7.86%
EDIT Editas Medicine	-5.41%	-2.78%	+35.48%	+61.54%	-58.90%
FDMT 4D Molecular Therapeutics	-8.72%	-13.73%	+8.02%	+2.17%	-83.57%
MLYS Mineralys Therapeutics	+2.15%	+2.38%	-13.72%	-17.94%	+14.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYH Community Health Systems	3.0612 of 5 stars	2.0	3.0	4.5	0.0	2.5	0.6
EDIT Editas Medicine	3.8097 of 5 stars	3.2	2.0	4.2	1.4	2.5	0.6
FDMT 4D Molecular Therapeutics	1.9667 of 5 stars	3.3	3.0	0.0	0.6	1.7	0.6
MLYS Mineralys Therapeutics	2.8278 of 5 stars	3.4	3.0	0.0	2.0	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYH Community Health Systems	2.00	Hold	$4.17	23.42% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	123.81% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	683.97% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	134.20% Upside

Current Analyst Ratings Breakdown

Latest CYH, FDMT, MLYS, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/29/2025	CYH Community Health Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$2.00 ➝ $3.50
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYH Community Health Systems	$12.63B	0.04	$2.58 per share	1.31	($12.06) per share	-0.28
EDIT Editas Medicine	$32.31M	5.44	N/A	N/A	$1.63 per share	1.29
FDMT 4D Molecular Therapeutics	$40K	4,366.60	N/A	N/A	$11.05 per share	0.34
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYH Community Health Systems	-$516M	-$3.68	N/A	13.50	N/A	-3.85%	N/A	-0.87%	7/23/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)

Latest CYH, FDMT, MLYS, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
4/23/2025	Q1 2025	CYH Community Health Systems	-$0.10	-$0.03	+$0.07	-$0.10	$3.10 billion	$3.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYH Community Health Systems	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYH Community Health Systems	N/A	1.44	1.30
EDIT Editas Medicine	N/A	3.08	3.08
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
MLYS Mineralys Therapeutics	N/A	26.48	26.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYH Community Health Systems	84.99%
EDIT Editas Medicine	71.90%
FDMT 4D Molecular Therapeutics	99.27%
MLYS Mineralys Therapeutics	84.46%

Insider Ownership

Company	Insider Ownership
CYH Community Health Systems	11.70%
EDIT Editas Medicine	1.90%
FDMT 4D Molecular Therapeutics	9.60%
MLYS Mineralys Therapeutics	33.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYH Community Health Systems	60,000	140.31 million	123.89 million	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable

CYH, FDMT, MLYS, and EDIT Headlines

Recent News About These Companies

Equities Analysts Offer Predictions for MLYS Q2 Earnings

June 21 at 1:17 AM | americanbankingnews.com

Research Analysts Issue Forecasts for MLYS Q2 Earnings

June 19, 2025 | marketbeat.com

Mineralys enhances lorundrostat data package ahead of planned NDA

June 18, 2025 | thepharmaletter.com

Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal

June 18, 2025 | tipranks.com

Mineralys Therapeutics (NASDAQ:MLYS) Given Buy Rating at HC Wainwright

June 18, 2025 | americanbankingnews.com

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

June 17, 2025 | benzinga.com

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?

June 17, 2025 | marketbeat.com

Mineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC Wainwright

June 17, 2025 | marketbeat.com

Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating

June 17, 2025 | tipranks.com

Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2

June 17, 2025 | fiercebiotech.com

Mineralys Therapeutics stock jumps after positive kidney disease trial data

June 17, 2025 | investing.com

Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial

June 17, 2025 | msn.com

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

June 17, 2025 | globenewswire.com

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?

June 16, 2025 | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen

June 14, 2025 | marketbeat.com

Jefferies initiates Mineralys Therapeutics stock with hold rating

June 12, 2025 | uk.investing.com

Jefferies Initiates Coverage of Mineralys Therapeutics (MLYS) with Hold Recommendation

June 12, 2025 | msn.com

Wellington Management Group LLP Has $1.13 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

June 7, 2025 | marketbeat.com

Mineralys Therapeutics: Merits A Small 'Speculative' Holding

June 3, 2025 | seekingalpha.com

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.9% - Should You Sell?

May 31, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Raises Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYH, FDMT, MLYS, and EDIT Company Descriptions

Community Health Systems NYSE:CYH

$3.38 +0.07 (+1.99%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$3.36 -0.02 (-0.47%)

As of 06/23/2025 04:34 PM Eastern

Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee.

Editas Medicine NASDAQ:EDIT

$2.10 -0.12 (-5.41%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.24%)

As of 06/23/2025 07:56 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$3.77 -0.36 (-8.72%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$3.84 +0.06 (+1.72%)

As of 06/23/2025 07:47 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Mineralys Therapeutics NASDAQ:MLYS

$13.77 +0.29 (+2.15%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$13.77 0.00 (0.00%)

As of 06/23/2025 06:20 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time